Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(...
DARMSTADT, Germany and NEW YORK, Feb. 17, 2019 /PRNewswire-AsiaNet/ -- Not intended for US, Canada and UK-based media- JAVELIN Renal 101 shows significant improvement in progression-free survivalwith a hazard ratio of 0.69 in patients regardless of PD-L1 expression- US FDA has granted Priority Review to BAV...
Authors: LATEST ASIANET NEWS RELEASES